Last reviewed · How we verify

NCT07062575

Exoskeleton Training at Home to Assist Participants With Spinal Cord Injuries to Perform Ambulatory Functions.

Suspended NA Last updated 27 January 2026
What this trial tests

NA trial testing ABLE Daily in Spinal Cord Injury in 10 participants. Suspended.

Timeline
19 June 2025
Primary endpoint
30 June 2026
30 June 2026

Quick facts

Lead sponsorABLE Human Motion S.L.
PhaseNA
StatusSuspended
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment10
Start date19 June 2025
Primary completion30 June 2026
Estimated completion30 June 2026
Sites1 location across Netherlands

Drugs / interventions tested

Conditions studied

Sponsor

ABLE Human Motion S.L.

Who can join

18 and older, any sex, with Spinal Cord Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to to confirm the safety and performance of the ABLE Daily to perform ambulatory functions in home and community settings for people with spinal cord injury. The experimental period will cover the training period with the ABLE Daily exoskeleton (3 weeks of use at the investigational site with a total of 9 sessions) and the home period (12 weeks of personal use at home and community environments).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Spinal Cord Injury

Currently open trials in the same condition.

Other ABLE Human Motion S.L. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07062575.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing